Skip to main content
SpringerLink
Log in

Reversible Inhibitors of Monoamine Oxidase A (RIMAs)

Where Can We Go from Here?

  • Chapter
Antidepressants

Part of the book series: Contemporary Neuroscience ((CNEURO))

  • 147 Accesses

Abstract

The newest class of antidepressant monoamine oxidase inhibitors in the clinic is the selective reversible inhibitors of monoamine oxidase A (RIMAs). These are considerably safer than the older, nonselective irreversible monoamine oxidase inhibitors (MAOIs), in that they have much less interaction with tyramine and certain drugs. Many trials have shown them to be of benefit in depression, and there is room for more variants of this type of drug to be developed. However, RIMAs also have less effect on both 5-hydroxytryptamine and dopamine oxidation than the older drugs, and it is possible that they are also less effective as antidepressants. In this chapter, it is suggested that nonselective but reversible monoamine oxidase inhibitors, a class of drug not yet tried in the clinic, might combine the efficacy of the old drugs and retain a greater safety margin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Glover, V. and Sandler, M. (1986) Clinical chemistry of monoamine oxidase. Cell Biochem. Funct. 4, 89–97.

    Article  PubMed  CAS  Google Scholar 

  2. Zheng-Yi, C., Hotamisligil, G. S., Huang, J.-Q., et al. (1991) Structure of the human gene for monoamine oxidase type A. Nucleic Acids Res. 19, 4537–4541.

    Article  Google Scholar 

  3. Tivol, E. A., Shalish, C., Schuback, D. E., et al. (1996) Mutational analysis of the human MAO A gene. Am. J. Med. Genet. 67, 92–97.

    Article  PubMed  CAS  Google Scholar 

  4. Lenders, J. W. M., Eishofer, G., Abeling, N. G., et al. (1996) Specific genetic deficiencies of the A and b isoenzymes of monoamine oxidase are characterised by distinct neuro-chemical and clinical phenotypes. J. Clin. Invest. 97, 1010–1019.

    Article  PubMed  CAS  Google Scholar 

  5. Chen, Z.-C., Denney, R. M., and Breakfield, X. O. (1995) Norrie disease and MAO genes: nearest neighbours. Human Molec Genet. 4, 1729–1737.

    Article  CAS  Google Scholar 

  6. Davis, W. A. (1958) The history of Marsilid J. Clin. Exp. Psychpath. 6(2 (Suppl), 1–10.

    Google Scholar 

  7. Zeller, E. A., Barsky, J., Fouts, J. R., et al. (1952) Influence of isonicotinic acid hydrazine (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia 8, 349–350.

    Article  CAS  Google Scholar 

  8. Kline, N. S. (1970) Monoamine oxidase inhibitors: an unfinished picaresque tale, in Discoveries in Biological Psychiatry Ayd, F.J. and Blackwell, B., ed. Lippincott, Philadelphia, pp. 194–204.

    Google Scholar 

  9. Loomer, H. R, Saunders, J. C., and Kline, N. A. (1957) Clinical and pharmacological evaluation of iproniazid as a psychic energizer, in Research in Affects Psychiatric Research Reports No 8 of the American Psychiatric Association. Cleghorn, R. A., ed Washington DC, pp. 129–141.

    Google Scholar 

  10. Report to the MRC. (1965) Clinical trial of the treatment of depressive illness. BMJ, 881.

    Google Scholar 

  11. Glover, V., Sandler, M., Owen, F., and Riley, G. J. (1977) Dopamine is a monoamine oxidase B substrate in man. Nature, 265, 80–81.

    Article  PubMed  CAS  Google Scholar 

  12. Knoll, J. (1993) The pharamcological basis of the beneficial effects of (-)-deprenyl (selegeline) in Parkinson’s and Alzheimer’s disease. J. Neur. Transm. 40 (Suppl), 69–93.

    CAS  Google Scholar 

  13. Mendis, N., Pare, C. M. B., Sandler, M., Glover, V., and Stern, G. (1981) Is the failure of (-)-deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression, related to its freedom from the cheese effect? Psychopharmacology 72, 275–277.

    Article  Google Scholar 

  14. Bieck, R. R., Antonin, K.-H., and Schulz, R. (1993) Clinical pharmacology of MAO inhibitors, in Monoamine Oxidase Yasuhara, H., ed. VSP. pp. 177–196.

    Google Scholar 

  15. Laux, G., Volz, H.-R, and Moller, H.-J. (1995) Newer and older monoamine oxidase inhibitors. CNS Drugs 3, 145–158.

    Article  CAS  Google Scholar 

  16. Rovei, V., Caille, D., Curet, O., Ego, D., and Jarreau, F.-X. (1994) Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor. J. Neural Transm. 41 (Suppl), 339–347.

    CAS  Google Scholar 

  17. Paykel, E. S. (1995) Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in depression. Acta Psychiatr. Scand. 91 (Suppl 386), 22–27.

    Article  Google Scholar 

  18. Nutt, D. and Glue, P. (1989) Monoamine oxidase inhibitors: rehabilitation from recent research? Brit. J. Psychiatry 154, 287–291.

    Article  CAS  Google Scholar 

  19. Liebowitz, M. R., Hollander, E., Schneier, F., et al. (1990) Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatry Scand. 360 (Suppl), 29–34.

    Article  CAS  Google Scholar 

  20. Berry, M. D., Jurio, A. V., and Paterson, I. A. (1994) The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog. Neurobiol. 42, 375–391.

    Article  PubMed  CAS  Google Scholar 

  21. Singer, T. R, Von Korff, R. W., and Murphy, D. L. (1979) Monoamine Oxidase: Structure, Function and Altered Function. New York: Academic.

    Google Scholar 

  22. Willoughby, J., Glover, V., and Sandler, M. (1988) Histochemical localisation of MAO A and B in rat brain. J. Neural. Transm. 74, 29–42.

    Article  PubMed  CAS  Google Scholar 

  23. Konradi, C., Kornhuber, J. K., Froelich, L., et al. (1989) Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 33, 383–400.

    Article  PubMed  CAS  Google Scholar 

  24. Luque, J. M., Kwan, S.-W., Abell, C. W., et al. (1995) Cellular expression of mRNAs encoding monoamine oxidases A and B in the rat central nervous system J. Comp. Neurol. 363, 665–680.

    Article  PubMed  CAS  Google Scholar 

  25. Saura, J., Bleuel, Z., Urlich, J., et al. (1996) Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radiography and in situ hybridization histochemistry. Neuroscience 70, 755–774.

    Article  PubMed  CAS  Google Scholar 

  26. Glover, V., Elsworth, J., and Sandler, M. (1980) Dopamine oxidation and its inhibition by (-)-deprenyl in man. J. Neural. Transm. 16 (Suppl), 163–172.

    CAS  Google Scholar 

  27. Riederer, P. and Youdim, M. (1986) Brain monoamine oxidase activity and monoamine metabolism in Parkinson patients treated with 1-deprenyl. J. Neuro’chem. 46, 1349–1356.

    Article  Google Scholar 

  28. Celada, P. and Artigas, F. (1993) Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat. Naunyn-Schmiedebergs Arch. Pharmacol. 347, 583–590.

    Article  PubMed  CAS  Google Scholar 

  29. Celada, P., Bel, N., and Artigas, F. (1994) The effects of brofaramine, a reversible MAO-A inhibitor, on extracellular serotonin in the raphe nucei and frontal cortex of freely moving rats. J. Neural. Transm. 41 (Suppl), 357–363.

    CAS  Google Scholar 

  30. Curet, O., Damoiseau, G., Labsune, J.-P. et al. (1994) Effects of béfloxatone, a new potent reversible MAO A inhibitor, on cortex and striatum monoamines in freely moving rats. J. Neural. Transm 41 (Suppl), 349–355.

    CAS  Google Scholar 

  31. O’Reilly, R. L. and Davis, B. A. (1994) Phenylethylamine and schizophrenia. Prog. NeuroPsychopharmacol. Biol. Psychiatry 18, 63–75.

    Article  Google Scholar 

  32. Amrein, R., Allen, S. R., Vranesic, D., and Stahl, M. (1988) Antidepressant drug therapy: associated risks. J. Neural. Transm. 26 (Suppl), 73–86.

    CAS  Google Scholar 

  33. Da Prada, M., Zurcher, G., Wuthrich, I., and Haefely, W. E. (1988)’ On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J. Neural. Transm. 26(Suppl), 31–56.

    Google Scholar 

  34. Korn, A., Wagner, B., Moritz, E., and Dingemanse, J. (1996) Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemidé and selegeline. Eur. J. Clin. Pharmacol. 49, 273–278.

    Article  PubMed  CAS  Google Scholar 

  35. Glover, V. (1993) Trials and tribulations with tribulin. Biogenic Amines 9, 443–452.

    CAS  Google Scholar 

  36. Glover, V., Halket, J. M., Watkins, P. J., Clow, A., Goodwin, B. L, and Sandler, M. (1988) Isatin: identity with the purified monoamine oxidase inhibitor tribulin. J. Neurochem. 51, 656–659.

    Article  PubMed  CAS  Google Scholar 

  37. Medvedev, A. E., Goodwin, B. L., Halket, J., Sandler, M., and Glover, V. (1995) Monoamine oxidase A-inhibiting components of urinary tribulin: purification and identification. J. Neur. Transm. 9, 225–237.

    Article  CAS  Google Scholar 

  38. Bhattacharya, S. K., Banerjee, R K., Glover, V., and Sandler, M. (1991) Augmentation of rat brain endogenous monoamine oxidase inhibitory activity (tribulin) by electroconvulsive shock. Neurosci. Lett. 125, 65–68.

    Article  PubMed  CAS  Google Scholar 

  39. Barden, N., Reul, J. M. H. M., and Holsboer, F. (1995) Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocrtical system? TINS 18, 6–11.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Vivette Glover
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Laboratory of Neuroscience, National Institutes of Health, Bethesda, MD, USA

    Phil Skolnick

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Glover, V. (1997). Reversible Inhibitors of Monoamine Oxidase A (RIMAs). In: Skolnick, P. (eds) Antidepressants. Contemporary Neuroscience. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-474-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-474-0_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-048-9

  • Online ISBN: 978-1-59259-474-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation